RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
NCT00936858
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Thyroid Cancer
Interventions
DRUG:
RAD001
Sponsor
Dana-Farber Cancer Institute
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]